Variability in COVID-19 Vaccine Response Among People With Cancer

Hoerger, Michael; Gerhart, James; Swartz, Maria C.

doi:10.1001/jamaoncol.2022.5874

Cited by 10 publications

(26 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, they reported that patients with metastatic disease (stage IV) had lower anti-S antibody titers with a consequent higher risk of SARS-CoV-2 breakthrough infection. These results should encourage health professionals to create a more comprehensive strategy to support the pandemic-related needs of the frailest patients [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up

Lasagna

Cassaniti

Arena

et al. 2023

IJMS

View full text Add to dashboard Cite

The role and durability of the immunogenicity of the BNT162b2 mRNA vaccine against severe acute respiratory virus 2 (SARS-CoV-2), in cancer patients one year after receiving the third dose have to be elucidated. We have prospectively evaluated the long-term immunogenicity of the third dose of the SARS-CoV-2 BNT162b2 mRNA vaccine in 55 patients undergoing active treatment. Neutralizing antibody (NT Ab) titers against Omicron variants and total anti-trimeric S IgG levels were measured one year after the third dose. Heparinized whole-blood samples were used for the assessment of the SARS-CoV-2 interferon-γ release assay (IGRA). Thirty-seven patients (67.3%) showed positive total anti-trimeric S IgG one year after the third dose. Looking at the T-cell response against the spike protein, the frequency of responder patients did not decrease significantly between six and twelve months after the third dose. Finally, less than 20% of cancer patients showed an undetectable NT Ab titer against BA.1 and BA.5 variants of concern (VOCs). Underlying therapies seem to not affect the magnitude or frequency of the immune response. Our work underlines the persistence of humoral and cellular immune responses against BNT162b2 in a cohort of cancer patients one year after receiving the third dose, regardless of the type of underlying therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up

Lasagna

Cassaniti

Arena

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…The reporting of cardiovascular complications stemming from COVID-19 in cancer patients has been limited. Many cancer patients are treated with immune checkpoint inhibitors (ICI), which have been known to be associated with myocarditis; however, this patient’s chemotherapy regimen did not include any ICIs [ 40 ]. This patient’s cancer treatment was held until she made a full recovery from COVID-19 and associated complications.…”

Section: Discussionmentioning

confidence: 99%

“…However, the subsequently confirmed metastatic breast cancer may have made her more vulnerable to developing this uniquely complicated case of COVID-19. It may also have made her response to the vaccine less robust [ 40 ]. It is also possible that the COVID-19 infection was simply coincident with the encephalitis and myocarditis.…”

Section: Discussionmentioning

confidence: 99%

A Rare Single Case of COVID-19-Induced Acute Myocarditis and Encephalopathy Presenting Simultaneously

et al. 2023

View full text Add to dashboard Cite

The ongoing coronavirus disease 2019 (COVID-19) pandemic may result in cardiovascular complications such as myocarditis, while encephalitis is a potentially life-threatening COVID-19-associated central nervous system complication. This case illustrates the possibility of developing severe multisystem symptoms from a COVID-19 infection, despite having received the COVID-19 vaccine within the year. Delay in treatment for myocarditis and encephalopathy can lead to permanent and possibly fatal damage. Our patient, a middle-aged female with a complicated medical history, initially came in without characteristic manifestations of myocarditis such as shortness of breath, chest pain, or arrhythmia, but with an altered mental status. Through further laboratory tests, the patient was diagnosed with myocarditis and encephalopathy, which were resolved within weeks through medical management and physical/occupational therapy. This case presentation describes the first reported case of concomitant COVID-19 myocarditis and encephalitis after receiving a booster dose within the year.

show abstract

“…To the Editor We were impressed by the promising results from the national COVID-19 and cancer cross-sectional evaluation conducted by Lee et al, who reported an association of SARS-CoV-2 spike protein antibody vaccine response with infection severity among patients with cancer; these findings can help develop a health care strategy to protect vulnerable individuals . However, we still have a few concerns regarding this study.…”

mentioning

confidence: 94%

Association of SARS-CoV-2 Antibody Level With Risk of Infection or Hospitalization

2023

View full text Add to dashboard Cite

appendiceal from cecal malignant tumors may also yield misclassification across these tumor types. We outlined that clinical histories, including appendix cancer diagnosis, were ascertained from clinician-completed test requisition forms (alongside clinical documentation when provided) so as not to imply that there was universal pathologic annotation of cases. 1 However, we believe that a potential conflation of appendiceal and cecal malignant tumors lends additional support to genetic testing in patients with appendix cancer-particularly those younger than 50 years at diagnosis (early-onset). Genetic testing results could lead to a prompt pathology re-review, which could in turn either prevent misdiagnoses or, if pathology is confirmed, provide a more definitive characterization into the role of germline predisposition in appendix cancer. This highlights the importance of driving efforts forward to improve gene discovery specific to appendix cancer predisposition and to validate our findings, which we mentioned in the article.In light of the potential pathological discordance that complicates a clinical diagnosis of appendiceal cancer, it is also likely that we currently have an incomplete understanding of the true/generalizable population of patients with appendiceal cancer. For now, we highlighted that patients with appendix cancer with a family history of cancer (and potentially a hereditary cancer syndrome) may have been overrepresented in this cohort, who underwent clinical multigene panel testing given the current absence of genetic testing guidelines specific to this population. Moving forward, these topics remain integral to consider in elucidating a potential link to Lynch syndrome and tailoring recommendations for germline testing in this patient population using prospective cohorts of patients with appendix cancer (NCT05734430) that curate clinical, pathological, genetic, biological, and individuallevel information.

show abstract

Variability in COVID-19 Vaccine Response Among People With Cancer

Cited by 10 publications

References 12 publications

Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up

Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up

A Rare Single Case of COVID-19-Induced Acute Myocarditis and Encephalopathy Presenting Simultaneously

Association of SARS-CoV-2 Antibody Level With Risk of Infection or Hospitalization

Contact Info

Product

Resources

About